Targeted Therapy Development in Acute Myeloid Leukemia.
Ontology highlight
ABSTRACT: Therapeutic developments targeting acute myeloid leukemia (AML) have been in the pipeline for five decades and have recently resulted in the approval of multiple targeted therapies. However, there remains an unmet need for molecular treatments that can deliver long-term remissions and cure for this heterogeneous disease. Previously, a wide range of small molecule drugs were developed to target sub-types of AML, mainly in the relapsed and refractory setting; however, drug resistance has derailed the long-term efficacy of these as monotherapies. Recently, the small molecule venetoclax was introduced in combination with azacitidine, which has improved the response rates and the overall survival in older adults with AML compared to those of chemotherapy. However, this regimen is still limited
SUBMITTER: Totiger TM
PROVIDER: S-EPMC9953553 | biostudies-literature | 2023 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA